23andMe's future prompts more concern, as genomic data analysis advances TechCrunch

Customers of genetic data outfit 23andMe may be at greater risk than they realize, suggests a New York Times story that argues that the company's troubles may be short-lived compared to the long-term threat facing the roughly 15 million people facing 23andMe if it can't continue. As an ongoing concern.

Certainly, 23andMe founder and CEO Anne Wojcicki's hopes are increasingly out of reach. After a major breach and the resignation of its independent directors, the company, once valued at $6 billion, is now valued at $150 million. It will be delisted next month. Press stories are not helping. (Would you buy a DNA kit of this?)

The company says it's committed to “following the laws that govern the data we collect,” but if it can't do so soon, it's worrisome, the Yale biomedical professor told the Times. He notes that hacked credit cards can be replaced, while a gnome cannot. Meanwhile, he added, technology that analyzes genomes is advancing. Chances are it will become more revealing, too.